Overview

Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
THe primary objective is to estimate the response rate at 6 months to Gleevec® in patients with plexiform neurofibromas
Phase:
Phase 2
Details
Lead Sponsor:
Indiana University
Treatments:
Imatinib Mesylate